INDIA—In a innovative move, TechInvention Lifecare Pvt. Ltd., a leading Indian biotech firm, has unveiled a monumental initiative with the inauguration of the Global Collaborative Centre for Medical Countermeasures (GCMC) in Navi Mumbai, strategically positioned near the forthcoming international airport.

This significant investment, totaling approximately US$ 15 million, was formally declared on February 28, 2024, marking a pivotal step forward in bolstering global health security and fortifying pandemic readiness.

Renowned for its pioneering approach, TechInvention has earned acclaim for championing the ‘One Health’ paradigm, seamlessly integrating diagnostics, vaccinations, and biotherapeutics to cater to both human and animal welfare sectors.

The establishment of GCMC aims to address the requirements of diverse stakeholders, encompassing public and private enterprises, academia, startups, MSMEs, and research and development organizations.

The centre pledges to furnish a holistic ecosystem, streamlining the transition from research and development to large-scale production adhering to Good Manufacturing Practice (GMP) standards for pre-clinical and clinical batches, while securing the requisite regulatory endorsements.

GCMC’s global significance was acknowledged during the 2nd World Local Production Forum held in The Hague from November 6–8, 2023, under the auspices of the World Health Organization (WHO).

Aligned with the WHO’s rallying call for action, CEPI’s ambitious 100-day mission, India’s National Biotechnology Development Strategy (2020-2025), and other pivotal global initiatives, the GCMC epitomizes a forward-looking approach towards enhancing medical countermeasures.

Positioned as an eco-friendly hub, GCMC stands poised to address critical medical countermeasures encompassing the entire spectrum of vaccine development, spanning from strain identification to supply chain management, alongside biotherapeutics and diagnostics catering to both human and veterinary domains, all the while ensuring environmentally sustainable manufacturing practices.

This pioneering endeavour underscores the essence of the One Health ethos, accentuating the interconnectedness of human, animal, and environmental well-being.

Mr. Syed S. Ahmed, Director and CEO of TechInvention, underscored the prevailing disparities in biologics equity, attributing them to the gap in translational research dissemination between centers of excellence and regional manufacturing hubs operating under a ‘hub and spoke’ model.

He expressed confidence that GCMC would serve as a vital intervention, fortifying the existing hubs by delivering scaled-up, regulatory-approved, cost-effective, and non-infringing biosolutions derived from indigenous research endeavours and international centres of excellence.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.